Ohr Pharmaceutical Reports Fiscal Year 2016 Financial and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ohr Pharmaceutical Reports Fiscal Year 2016 Financial and Business Results

NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP ), an ophthalmology research and development company, today reported results for its fourth quarter and fiscal year ended September 30, 2016.

“Fiscal year 2016 was another highly productive year for Ohr, as we made significant progress in advancing both our lead candidate Squalamine for the treatment of wet AMD as well as our pipeline of sustained release drug candidates,” said Jason Slakter, MD, Chief Executive Officer of Ohr.  “Building off the Squalamine phase 2 results, we negotiated an SPA with the FDA in advance of commencing the pivotal phase 3 program.  This comprehensive phase 3 program is now underway which, if successful, will position us to bring an innovative, meaningful treatment to market that has the potential to improve vision outcomes beyond current therapies and set a new standard of care in wet AMD.”

Fiscal 2016 and Recent Corporate Highlights

  • Reached an agreement on a Special Protocol Assessment (SPA) with the US FDA on the design of Phase 3 trials for Squalamine lactate ophthalmic solution, 0.2% (“Squalamine”, also known as OHR-102) for patients with wet AMD. 
  • Appointed David M. Brown, MD to serve as the chair of the Steering Committee for the Phase 3 clinical program of Squalamine in wet-AMD.
  • Closed a public offering of shares of common stock and warrants resulting in net proceeds of approximately $6.9 million.

Fiscal 2016 Clinical and Development Program Highlights

  • In September, presented new data from the Phase 2 IMPACT study at the American Society of Retina Specialists (ASRS). Subjects with occult CNV <10mm 2 achieved final mean visual acuity outcomes of 71.7 letters with Squalamine combination therapy compared to 67.4 letters with Lucentis® monotherapy. The final mean visual acuity outcomes in the combination therapy group translates to approximately 20/40 vision (Snellen equivalent). This underscores the potential of Squalamine combination therapy to allow patients to reach higher levels of visual function and improve their overall quality of life.
  • In May, presented two posters on the Squalamine Phase 2 IMPACT study and OHR3031 sustained release in vivo studies at the Association for Research in Vision and Ophthalmology (ARVO) Conference.
  • In April, commenced enrollment in the Phase 3 clinical development program investigating Squalamine as a treatment to improve visual acuity for patients with wet AMD.
    • The Phase 3 program includes two double-masked, placebo-controlled, multicenter, international studies of Squalamine administered topically twice a day in patients with newly diagnosed wet AMD, in combination with Lucentis ® injections.
    • The primary endpoint in both studies is a measurement of visual acuity gain at nine months, which is the most clinically meaningful endpoint for wet AMD patients.  Subjects will be followed to two years for safety.
  • In November 2015, presented new data from the Phase 2 IMPACT Study in Wet-AMD at American Academy of Ophthalmology (AAO) Annual Meeting.
    • Data showed that the size of occult CNV at baseline, irrespective of a classic CNV component, was the most important factor in predicting treatment success with the combination of Squalamine plus Lucentis®. This correlation was not seen in the Lucentis® monotherapy group.
  • Also in November 2015, announced positive preclinical data in proprietary SKS sustained release technology.                      
    • In an animal model used to evaluate ophthalmic compounds, sustained supratherapeutic levels of active drug were achieved in target ocular tissues at all time points in the study.
    • The results serve as an important validation for the company's SKS sustained release technology which holds the promise of improving the standard of care in a number of ocular conditions.

Financial Results for the Fiscal Year ended September 30, 2016

  • For the year ended September 30, 2016, the Company reported a net loss of approximately $25.8 million, or ($0.82) per share, compared to a net loss of approximately $15.2 million, or ($0.54) per share in the same period of 2015.
  • For the year ended September 30, 2016, total operating expenses were approximately $24.6 million, consisting of $7.7 million in general and administrative expenses, $16.5 million of research and development expenses, and $1.2 million in depreciation and amortization.  This compares to total operating expenses of $17.8 million in the same period of 2015, comprised of approximately $7.5 million in general and administrative expenses, $8.8 million in research and development expenses, and $1.2 million in depreciation and amortization.
  • At September 30, 2016, the Company had cash and cash equivalents of approximately $12.5 million. This compares to cash and equivalents of approximately $28.7 million at September 30, 2015.
  • On December 7, 2016, the Company sold in a public offering, an aggregate of approximately 3,885,000 shares of its common stock, together with Series A common stock purchase warrants exercisable for up to an aggregate of approximately 1,942,500 shares of common stock and Series B common stock purchase warrants exercisable for up to an aggregate of approximately 3,885,000 shares of common stock.  Net proceeds from the offering were approximately $6.9 million, after deducting placement agent fees and estimated offering expenses payable but excluding the proceeds, if any, from the exercise of the Series A and Series B Warrants issued in the offering.

Conference Call & Webcast Thursday, December 22 at 5:00pm Eastern Time

Domestic:             877-407-0789
International:             201-689-8562
Conference ID:             13651651
Webcast:             http://public.viavid.com/index.php?id=122267

Replays – Available through December 29, 2016

Domestic:               844-512-2921
International:               412-317-6671
Conference ID:               13651651

About Ohr Pharmaceutical, Inc. Ohr Pharmaceutical, Inc. (Nasdaq: OHRP ) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in a Phase 3 clinical program for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.  Additional information on the company may be found at www.ohrpharmaceutical.com . Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K discuss some of the important risk factors that may affect our business, results of operations and financial condition.

Lucentis ® is a registered trademark of Genentech Inc.

 
OHR PHARMACEUTICAL, INC.
Consolidated Balance Sheets
(Unaudited)
               
      September 30,   September 30,
      2016     2015  
ASSETS
CURRENT ASSETS      
  Cash $ 12,546,890     $ 28,697,323  
  Prepaid expenses and other current assets   738,118       338,713  
               
    Total Current Assets   13,285,008       29,036,036  
               
EQUIPMENT, net   198,631       248,753  
               
OTHER ASSETS          
  Security deposit   12,243       12,243  
  Intangible assets, net   15,208,219       16,332,863  
  Goodwill   740,912       740,912  
               
    TOTAL ASSETS $ 29,445,013     $ 46,370,807  
               
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES          
  Accounts payable and accrued expenses $ 4,394,068     $ 1,592,348  
  Notes payable   87,798       48,063  
  Contingent consideration   -       2,239,603  
               
    Total Current Liabilities   4,481,866       3,880,014  
               
    TOTAL LIABILITIES   4,481,866       3,880,014  
               
STOCKHOLDERS' EQUITY          
  Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively   -       -  
  Common stock; 180,000,000 shares authorized, $0.0001 par value, 32,076,396 and 30,331,309 shares issued and outstanding, respectively     3,207       3,033  
  Additional paid-in capital   109,237,551       100,999,173  
  Accumulated deficit   (84,277,611 )     (58,511,413 )
               
    Total Stockholders' Equity   24,963,147       42,490,793  
    TOTAL LIABILITIES AND          
    STOCKHOLDERS' EQUITY $ 29,445,013     $ 46,370,807  
               
OHR PHARMACEUTICAL, INC.
Consolidated Statements of Operations
(Unaudited)
                     
For the Year Ended September 30,  
       
      2016     2015     2014  
                     
OPERATING EXPENSES                
                     
General and administrative $ 7,656,327     $ 7,509,601     $ 4,287,205  
                     
Research and development   16,460,714       8,777,519       4,369,413  
                     
Depreciation and amortization   1,189,276       1,179,254       466,306  
                     
Gain on settlement of accounts payable   (710,264 )     -       -  
                     
Impairment of Intangibles   -       338,906       -  
                     
    OPERATING LOSS   24,596,053       17,805,280       9,122,924  
                     
OTHER INCOME (EXPENSE)                
  Change in fair value of contingent consideration     (1,185,667 )     2,637,756       -  
  Share in losses on investment in joint venture   -       (103,143 )     (10,643 )
  Other income and expense   3,419       42,966       8,479  
  Interest income (expense), net   12,103       (5,977 )     (5,576 )
  Royalty income   -       35,813       -  
                     
    Total Other Income (Expense)   (1,170,145 )     2,607,415       (7,740 )
                     
LOSS FROM OPERATIONS BEFORE                
  INCOME TAXES   (25,766,198 )     (15,197,865 )     (9,130,664 )
                     
PROVISION FOR INCOME TAXES   -       -       -  
                     
NET LOSS $ (25,766,198 )   $ (15,197,865 )   $ (9,130,664 )
                     
BASIC AND DILUTED LOSS PER SHARE $ (0.82 )   $ (0.54 )   $ (0.41 )
                     
WEIGHTED AVERAGE  NUMBER                
OF SHARES OUTSTANDING:                
  BASIC AND DILUTED   31,349,223       28,404,405       22,141,538  
                     
OHR PHARMACEUTICAL, INC.
Consolidated Statements of Cash Flows
(Unaudited)
                       
        For the Twelve Months Ended
        September 30,
        2016     2015     2014  
OPERATING ACTIVITIES                
  Net loss   $ (25,766,198 )   $ (15,197,865 )   $ (9,130,664 )
  Adjustments to reconcile net loss to net cash                
   used by operating activities:                
    Common stock issued for services   1,754,814       635,288       -  
    Warrants issued for services   -       8,559       1,177,095  
    Stock option expense   2,913,626       3,579,788       2,074,487  
    Change in fair value of contingent consideration   1,185,667       (2,637,756 )     -  
    Share in losses on investment in joint venture   -       103,143       10,643  
    Depreciation   64,632       40,623       17,850  
    Amortization of intangible assets   1,124,644       1,138,631       448,456  
    Impairment of intangibles   -       338,906       -  
    Gain on settlement of accounts payable   (710,264 )     (40,636 )     -  
  Changes in operating assets and liabilities                
    Prepaid expenses and deposits   (64,794 )     7,214       105,823  
    Accounts payable and accrued expenses   3,511,984       1,331,120       (63,822 )
                       
      Net Cash Used in Operating Activities   (15,985,889 )     (10,692,985 )     (5,360,132 )
                       
INVESTING ACTIVITIES                
    Acquisition of SKS Ocular's assets   -       -       (3,500,000 )
    Investment in joint venture   -       (100,000 )     (13,786 )
    Purchase of property and equipment   (14,510 )     (184,951 )     (1,083 )
      Net Cash Used in Investing Activities   (14,510 )     (284,951 )     (3,514,869 )
                       
FINANCING ACTIVITIES                
  Proceeds for issuance of common stock for cash   -       26,582,998       16,876,000  
  Proceeds from warrants exercised for cash   26,041       80,003       260,752  
  Repayments of short-term notes payable   (176,075 )     (208,236 )     (164,152 )
                       
    Net Cash Provided by/ (Used in) Financing Activities   (150,034 )     26,454,765       16,972,600  
                       
NET CHANGE IN CASH   (16,150,433 )     15,476,829       8,097,599  
CASH AT BEGINNING OF PERIOD   28,697,323       13,220,494       5,122,895  
                       
CASH AT END OF PERIOD $ 12,546,890     $ 28,697,323     $ 13,220,494  
                       
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION   -              
  CASH PAID FOR:                
    Interest $ 6,071     $ 5,977     $ 5,576  
    Income Taxes   -       -       -  
                       
  NON CASH FINANCING ACTIVITIES:                
    Settlement of contingent consideration $ 3,425,270     $ -     $ -  
    Financing of insurance premiums through issuance of short term notes   215,810       212,400       194,000  
    Subscription receivable from exercise of warrants   118,801       -       -  
    Conversion of preferred for common stock   -       -       50  
    Noncash exercise of options and warrants   -       -       223  
    Common stock issued to acquire intangible assets   -       -       10,180,224  
    Common stock issued to settle accounts payable   -       50,000       50,000  
                       

 

Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 ir@ohrpharmaceutical.com LifeSci Advisors, LLC Michael Wood 646-597-6983 mwood@lifesciadvisors.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 199

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 26

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 118

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 68

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 21

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 88

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Hagerty's Fifth Film Win Keeps Its Media Engine Humming

Updated Category News Views 57

A lap record, a camera crew, and five straight trophies make a louder statement than another glossy corporate slogan. Hagerty won Best Journalism Film at the 2026 International Motor Film Awards on Nov. 14, held at the Petersen Automotive Museum in Los Angeles. The company has taken that particular award home five years running, powered again by Jason Cammisa and his...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 82

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 61

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 50

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading

Top 5 Most Recently Viewed Articles

Private Tutoring Insights: Learning from Finland's Education Method

Updated Category News Views 206

Exploring Finland's Educational Principles for Private Tutoring In today's rapidly evolving educational landscape, Tutors International passionately investigates various global education models. One system that stands out is Finland's renowned educational approach, widely admired for its emphasis on holistic learning and well-being. Tutors International's latest analysis...

Continue Reading
Charter Communications and Cox Communications Join Forces

Updated Category News Views 162

Charter Communications Merges with Cox Communications In a pivotal move for the telecommunications industry, Charter Communications and Cox Communications have entered into a definitive agreement to combine their companies. This merger signifies a significant consolidation within the sector, promising advancements in service delivery and enhanced operational efficiency...

Continue Reading
Investor Insights on Dyne Therapeutics: Understanding Risks

Updated Category News Views 568

Understanding the Current Situation of Dyne Therapeutics Dyne Therapeutics, Inc. (NASDAQ: DYN) is currently under scrutiny as Pomerantz LLP investigates potential claims on behalf of investors. The concerns arise regarding whether Dyne and its executives may have engaged in improper securities practices. Investors holding shares or contemplating an entry into the market...

Continue Reading
Scientology's New Campaign Aims to Inspire Global Engagement

Updated Category News Views 116

Scientology Launches Global Welcome Campaign The Church of Scientology International is excited to unveil its innovative Global Welcome to Scientology campaign. This initiative is a powerful effort focused on bringing people together and elevating the human experience through understanding and discovery. Inspiring Discovery Across the Globe With the aim of fostering a...

Continue Reading
Deborah R. Willig Shines in Lawdragon's Prestigious Award List

Updated Category News Views 241

Deborah R. Willig Recognized Among Leading Civil Rights Attorneys Willig, Williams & Davidson proudly announces that Deborah R. Willig, the firm's managing partner, has once again earned a spot in the esteemed Lawdragon 500 list of leading civil rights and plaintiff employment lawyers. This recognition underscores her unwavering commitment to advocating for workers'...

Continue Reading